AGIOS PHARMACEUTICALS, INC. Increase (Decrease) in Other Receivables
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Increase (Decrease) in Other Receivables of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2023-11-02
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in other receivables for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in other receivables for the quarter ending 2023-06-30 was $0.00.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in other receivables for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in other receivables for the quarter ending 2022-09-30 was $1.07M.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in other receivables for fiscal 2015 was $1.04M, a 55.44% decline from fiscal 2014.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in other receivables for fiscal 2014 was $2.33M.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month | Increase (Decrease) in Other Receivables 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | |||
| 2022-09-30 | $1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$1.59M derived: sum of 2 quarters · filed 2023-11-02 | -$604.00K 10-Q · filed 2023-11-02 | |
| 2022-06-30 | -$2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$1.67M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $987.00K 10-Q · filed 2023-05-04 | |||
| 2021-09-30 | -$1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $6.99M derived: sum of 2 quarters · filed 2022-11-03 | $6.99M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $8.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $8.13M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-07-29 | |||
| 2015-12-31 | $381.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | -$1.91M derived: sum of 2 quarters · filed 2016-02-26 | -$3.53M derived: sum of 3 quarters · filed 2016-02-26 | $1.04M 10-K · filed 2016-02-26 |
| 2015-09-30 | -$2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | -$3.91M derived: sum of 2 quarters · filed 2015-11-06 | $659.00K 10-Q · filed 2015-11-06 | |
| 2015-06-30 | -$1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $2.95M 10-Q · filed 2015-08-07 | ||
| 2015-03-31 | $4.57M 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $2.33M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |